Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study

Journal of Clinical Medicine

Alper Bilgic¹  Aditya Sudhalkar¹  Francesc March de Ribot²  Jesus H. Gonzalez-Cortes³  Vaishali Vasavada⁴  Thibaud Mathis⁵  Amro Abukashabah⁵  Laurent Kodjikian⁵ 

[1] Alphavision Augenarztpraxis, 27568 Bremerhaven, Germany;Department of Ophthalmology, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain;Department of Ophthalmology, Universitat Autonoma de Ciudad, Mexico City 06720, Mexico;Raghudeep Eye Hospital, Ahmedabad 380054, India;Service d’Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 69004 Lyon, France;

关键词: age-related macular degeneration;    anti-vascular endothelial growth factor;    brolucizumab;    exudation;    switch therapy;   

DOI  :  10.3390/jcm10132758

来源: DOAJ

【 摘 要 】

The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. The REBA study (real-world experience with brolucizumab in wet AMD) was a retrospective, observational, multicentric study that included 78 consecutive patients (105 eyes), with neovascular AMD, who received brolucizumab therapy. Both treatment-naive and switch-therapy patients were included. Switch therapy was based either on fluid recurrence, fluid recalcitrance, or inability to extend beyond q4/q6. All relevant data were collected. The primary outcome measure was change in best-corrected visual acuity (BCVA) over time. Secondary outcome measures included determination of change in central subfield thickness (CST) and complications. The mean baseline BCVA was 49.4 ± 5.4 letters and 40 ± 3.2 letters, and corresponding mean BCVA gain was +11.9 ± 3.9 letters (p = 0.011) and +10.4 ± 4.8 letters (p = 0.014) in the treatment-naive and switch-therapy groups, respectively. The change in CST was significantly decreased in the treatment-naive (p = 0.021) and the switch-therapy (p = 0.013) groups. The mean follow-up was 10.4 months in both groups. One patient in the switch-therapy group developed vascular occlusion and another a macular hole after the fifth brolucizumab injection. Both patients recovered uneventfully. In conclusion, patients showed a very good anatomical and functional response to brolucizumab therapy in the real world, regardless of prior treatment status, until the end of the follow-up period. Two significant untoward events were noted.

【 授权许可】

Unknown